Olomoucine |
رقم الكتالوجGC16520
One-Click Copy Product Info
|
Olomoucine هو مثبط تنافسي لـ ATP لـ CDKs
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 101622-51-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Olomoucine is an ATP-competitive CDK inhibitor [1].
Cyclin-dependent kinases (CDKs) play important roles in the regulation of the cell division cycle and are therefore promising targets for cancer therapy [1].
Olomoucine is an ATP-competitive CDK inhibitor with IC50 values of 7, 7, 7, 3 and 25 μM against CDC2/cyclin B, Cdk2/cyclin A and Cdk2/cyclin E kinases, the brain CDK5/p35 kinase and the ERK1/p44 MAP kinase, respectively [1]. In metaphase-arrested Xenopus egg extracts, Olomoucine inhibited M-phase-promoting factor activity. Olomoucine provided an anti-mitotic reagent that might preferentially inhibit certain steps of the cell cycle [1]. In interleukin-2-stimulated T lymphocytes (CTLL-2 cells), Olomoucine inhibited DNA synthesis and caused Gl arrest [2].
In rats after after spinal cord injury (SCI), olomoucine attenuated astroglial proliferation and glial scar formation, decreased lesion cavity and mitigated functional deficits. In rats following SCI, olomoucine significantly decreased the spinal cord edema formation, suppressed microglial proliferation and attenuated production of proinflammatory cytokines in the traumatic spinal cord. Olomoucine also attenuated neuronal cell death [3].
References:
[1]. Vesel J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994 Sep 1;224(2):771-86.
[2]. Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell. 1995;83(2-3):105-20.
[3]. Tian DS, Xie MJ, Yu ZY, et al. Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. Brain Res. 2007 Mar 2;1135(1):177-85.
| Cas No. | 101622-51-9 | SDF | |
| Chemical Name | 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol | ||
| Canonical SMILES | OCCNc1nc(NCc2ccccc2)c2ncn(C)c2n1 | ||
| Formula | C15H18N6O | M.Wt | 298.3 |
| الذوبان | ≤10mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL |
| 5 mM | 670.5 μL | 3.3523 mL | 6.7047 mL |
| 10 mM | 335.2 μL | 1.6762 mL | 3.3523 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A crystalline solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)